Anchiano Therapeutics (NASDAQ:ANCN) Shares Gap Down to $1.95

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) gapped down prior to trading on Thursday . The stock had previously closed at $1.95, but opened at $1.81. Anchiano Therapeutics shares last traded at $1.81, with a volume of 200 shares.

A number of equities analysts recently weighed in on ANCN shares. Zacks Investment Research lowered shares of Anchiano Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 13th. ValuEngine upgraded shares of Anchiano Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 2nd.

The stock’s 50 day moving average price is $1.75 and its 200 day moving average price is $1.31. The company has a market capitalization of $12.84 million, a price-to-earnings ratio of 11.53 and a beta of 0.89.

Anchiano Therapeutics (NASDAQ:ANCN) last posted its quarterly earnings data on Monday, November 16th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.10. On average, equities analysts anticipate that Anchiano Therapeutics Ltd. will post -1.81 earnings per share for the current year.

A hedge fund recently bought a new stake in Anchiano Therapeutics stock. FMR LLC acquired a new position in shares of Anchiano Therapeutics Ltd. (NASDAQ:ANCN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 43,000 shares of the company’s stock, valued at approximately $288,000. FMR LLC owned about 0.58% of Anchiano Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 10.98% of the company’s stock.

About Anchiano Therapeutics (NASDAQ:ANCN)

Anchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models.

Read More: What is the Nikkei 225 index?    

Receive News & Ratings for Anchiano Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anchiano Therapeutics and related companies with's FREE daily email newsletter.